Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals-Reference-Cited by-同舟云学术

Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals

Published:2019-05 Issue:5 Volume:51 Page:681-688
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Casadei Gardini Andrea^ORCID,Foschi Francesco Giuseppe,Conti Fabio,Petracci Elisabetta,Vukotic Ranka,Marisi Giorgia,Buonfiglioli Federica,Vitale Giovanni,Ravaioli Federico^ORCID,Gitto Stefano^ORCID,Verucchi Gabriella,Lenzi Marco,Bolondi Luigi,Mazzella Giuseppe,Brillanti Stefano^ORCID,Andreone Pietro

Funder

MSD

ABBVIE

GILEAD Sciences

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference49 articles.

1. New hepatitis C therapies: the toolbox, strategies, and challenges;Pawlotsky;Gastroenterology,2014

2. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience;Bielen;J Viral Hepat,2017

3. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy;Reig;J Hepatol,2016